Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in knee osteoarthritis

Joint Bone Spine

Volumn 70, Issue 4, 2003, Pages 276-281

  Kahan, André ^a   Lleu, Pierre Louis ^b   Salin, Laurence ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BOEHRINGER INGELHEIM   (France)

Author keywords

Cost effectiveness; Knee osteoarthritis; Synvisc ; Viscosupplementation

Indexed keywords

HYALURONIC ACID; HYLAN GF 20;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INJECTION PAIN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0041360310     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(03)00043-5     Document Type: Article

References (19)

1. Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger Jr TA, Felts WR, et al. Estimates of the prevalence of the selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989;16(4):427-41.
2. Cicuttini F, Spector T. Osteoarthritis in the aged. Epidemiological issues and optimal management. Drugs Aging 1995;6:409-20.
3. Levy E, Ferme A, Perocheau D, Bono I. Les coûts socio-économiques de l'arthrose en France. Rev Rhum 1993;60:63S-7S.
4. Bird W. Rheumatological audit - a general practice perspective. Eur J Rheumatol Inflamm 1994;14(Suppl 3):1-2.
5. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Eur J Clin Pharmacol 1994;55:220-32.
6. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. Arthritis Rheum 2000;43:1905-15.
7. Wobig M, Dickut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26 week controlled trial of efficacy and safety in osteoarthritic knee. Clin Ther 1998;20:410-23.
8. Adams ME, Atkinson MH, Lussier A, Schulz JI, Siminovitch KA, Wade JP, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc®) in the treatment of osteoarthritifis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995;3:213-26.
9. Bell M, Fallaha M, Lenczner E, Ranger P, Welsh P. Viscosupplementation with hylan G-F 20 in total knee replacement candidates: an effective pain management therapy that may delay surgery. Osteoarthritis Cartilage 2000;8:137-9.
10. Lussier A, Cividino AA, McFarlane C, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings form clinical practice in Canada. J Rheumatol 1996;23:1579-85.
11. Wulwik A, Bertocci S, Raude-Leroy V, Lleu PL. Efficacy and safety of Synvisc® in severe knee osteoarthritis (OA): experience from a large cohort of patients followed in private rheumatological practice. Ann Rheum Dis 2001;60:226.
12. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.
13. Vignon E, Lleu PL, Kahan A, Treves R, Naïm C, Valat JP. Etude multicentrique d'évaluation du coût, de l'efficacité et de la tolérance du traitement par Hylane-GF 20 chez des patients gonarthrosiques. Rev Rhum 1999;66:747 [abstract].
14. Altman RD. The classification of osteoarthritis. J Rheumatol 1995; 22(Suppl 43):42-3.
15. Brandt KD, Fife RS, Braunstein EM, Katz B. Radiographic grading of severity of knee osteoarthritis: relation of the Kellgren and Lawrence grade to a grade base on joint narrowing, and correlation with arthroscopic evidence of articular cartilage degeneration. Arthritis Rheum 1991;34:1381-6.
16. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974; 15:443-53.
17. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation - value in comparison with other assessment tests. Scand J Rheumatol 1987;65(S):85-9.
18. Bellamy N, Buchanan WW, Goldsmith CH, Cambell J, Stitt LWJ. Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
19. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.